AZOPT® (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor formulated for multidose topical ophthalmic use.
AZOPT® (brinzolamide ophthalmic suspension) 1% is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Published Studies Related to Azopt (Brinzolamide)
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. [2011.07]
BACKGROUND: To compare the efficacy and safety of timolol 0.5% versus brinzolamide 1.0% when added to travoprost monotherapy in patients with primary open-angle glaucoma or ocular hypertension... CONCLUSION: Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy, with timolol being slightly stronger 8 hours after instillation. Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost.
[Comparative study of the pressure lowering efficacy and variations in the ocular pulse amplitude between fixed combinations of dorzolamide/timolol and brinzolamide/timolol]. [2011.05]
OBJECTIVE: To determine possible differences in the intraocular pressure (IOP) and ocular pulse amplitude (OPA) lowering capacity of the fixed drug combinations dorzolamide/timolol and brinzolamide/timolol... CONCLUSIONS: Both fixed combinations were similarly effective in reducing intraocular pressure and ocular pulse amplitude. Adverse effects related to both treatments were mild and well-tolerated, though itching occurred most frequently in the eyes treated with dorzolamide/timolol. Copyright (c) 2011 Sociedad Espanola de Oftalmologia. Published by Elsevier Espana. All rights reserved.
Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. [2010.08]
PURPOSE: This study aims to identify progression factors in patients with primary open-angle glaucoma (POAG), including the effects of treatment with dorzolamide 2% or brinzolamide 1%, each added to timolol 0.5%... CONCLUSIONS: Progression increased with lower DBP, lower MAP, antihypertensive medication, lower EDV in the OA and SPCA, and higher RI in the OA and SPCA. The risk for progression in patients treated with DT was half that in patients treated with BT.
Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. [2009.09]
OBJECTIVE: To compare the efficacy of brimonidine, dorzolamide, and brinzolamide in reducing intraocular pressure (IOP) when used as adjunctive therapy to a prostaglandin analog (PGA)... CONCLUSIONS: The addition of brimonidine to a PGA provided greater IOP lowering than the addition of either dorzolamide or brinzolamide. Further studies are needed to evaluate the relative long-term efficacy and tolerability of these medications as adjunctive therapy to a PGA. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. [2009.06]
PURPOSE: To compare the effect on the retrobulbar hemodynamics and intraocular pressure (IOP) of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5% in patients with primary open-angle glaucoma (POAG)... CONCLUSIONS: Our results suggest augmented retrobulbar blood flow after 5 years of treatment with dorzolamide but not with brinzolamide, each added to timolol, in POAG patients.
Clinical Trials Related to Azopt (Brinzolamide)
A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin [Completed]
The purpose of this study was to assess the efficacy of adding Azopt dosed three times a day
to Xalatan as compared to that of adding placebo to Xalatan in patients with elevated
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension [Completed]
The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination
(Trav/Brinz) administered twice daily as compared to each of its marketed components
(TRAVATAN Z® solution and AZOPT® suspension) and to the unfixed combination of TRAVATAN Z®
plus AZOPT® in lowering intraocular pressure (IOP).
Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG) [Terminated]
To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1. 0%
(Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0. 004%
(Travatan) once daily. The study is double masked. The patients will receive either
treatment for 12 weeks.
Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension [Completed]
To evaluate the safety and efficacy of both BETAXON and AZOPT in pediatric patients.
Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks. Patients will
have vision tested, slit lamp exam, blood pressure and pulse checks at each visit. Patients
will have a dilated fundus exam and corneal measurements taken at first and last visit.
Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2% [Completed]
The purpose of this study was to evaluate the efficacy and safety of a fixed combination of
Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its
individual active components in patients with open-angle glaucoma and/or ocular
Reports of Suspected Azopt (Brinzolamide) Side Effects
Intraocular Pressure Increased (6),
Deafness Transitory (5),
Vision Blurred (5),
Drug Ineffective (4),
Sudden Cardiac Death (4),
Drug Hypersensitivity (4),
Diaphragmatic Paralysis (3), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Azopt has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Azopt review by 49 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || glaucoma|
|Dosage & duration:|| || 1 drop (dosage frequency: 2x daily) for the period of 5 years |
|Other conditions:|| || none|
|Other drugs taken:|| || betagan, alphagan|
|Benefits:|| || Although this is not available in generic, I am using the generic versions of alphagan and betagan in conjunction with this drug. Each drug was used independently to determine side effects before they were combined for treatment. (This was a many visit process! But the results have made it was worth it) This combination lowered my intraoccular pressure to the point that it was not necessary to have surgery - my next step since other combinations did not work.|
|Side effects:|| || Occasional burning when put into already irritated eyes.|
|Comments:|| || In conjunction with the above mentioned drops, I have had consistently lowered pressure with no side effects. |
Page last updated: 2011-12-09